! Age-related macular degeneration (AMD) is the major cause of blindness in people over age 55 in the U.S. and the developed world. One of the two forms of AMD is the ?dry? form for which currently there are no effective treatments. Consequently, there is an unmet medical need for development of new therapies for AMD. A number of retinal diseases including AMD are associated with mitochondrial dysfunction5. Dysfunctional mitochondria induce increased levels of reactive oxygen species (ROS), and defective metabolic activity. Autophagy loss also results in mitochondrial dysfunction and is suggested to increase susceptibility to oxidative stress and AMD. We have recently shown dysfunctional autophagy, increased ROS, and dysfunctional mitochondria in RPE derived from AMD donor eyes. However, the underlying mechanisms inducing these defective metabolic homeostases leading to AMD remain unknown. The Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha (PGC-1?) plays a major role in mitochondrial biogenesis and oxidative metabolism. It also regulates autophagy and mitophagy. PGC-1? activity is stimulated by two main factors: AMP-activated protein kinase (AMPK) and NAD+- dependent deacetylase, SIRT1. Preliminary evidence from our laboratory suggests that the AMPK/SIRT- 1/PGC-1? is down regulated in AMD RPE. Based on our preliminary data, we hypothesize that the repressed AMPK/SIRT1/PGC-1? pathway in RPE induces mitochondrial, autophagic dysfunction, and increased ROS production, which result in abnormal metabolic activity, lipid and glycogen accumulation, and drusen formation, leading to the AMD pathophysiology. To test our hypothesis, we have developed an inexhaustible AMD in vitro disease model by isolating native RPE from AMD donors' eyes followed by generation of iPSC, and their subsequent differentiation into RPE (AMD RPE-iPSC-RPE). We have also generated iPSC from RPE of age-matched normal donors (Normal RPE-iPSC-RPE) that serve as control. We confirmed that the AMD RPE-iPSC-RPE mimic the disease phenotypes of their parental donors, the primary AMD RPE, which validates our model. Additionally, we established an animal model to test the role of PGC-1? repression on RPE and retinal health and observed RPE and photoreceptor degeneration. We propose two aims:
Aim1 will test the role of AMPK/SIRT-1/PGC-1? pathway inhibition in dry AMD using our established in vitro model from AMD donors and AMD patients.
Aim2 will investigate the cellular and molecular mechanisms of PGC-1? actions on RPE and retinal health in a mouse model. Ultimately, these studies will provide insight into the molecular mechanisms of dry AMD and may facilitate development of new therapeutic interventions.
This proposal addresses critical issues of central importance to advance our understanding of the mechanisms of dry age-related macular degeneration (AMD). Those include: investigating how AMPK/SIRT/PGC-1? pathway could play a critical role in RPE functions and how its inactivity could contribute to the pathophysiology of AMD. The results and conclusions derived from this study will provide important information that could be used for development of novel treatment strategies for a devastating neurodegenerative disease of the visual system that primarily affects the elderly, minimizes their independence, and impairs their quality of life.
